IT202000000442A1 - Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia - Google Patents

Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia

Info

Publication number
IT202000000442A1
IT202000000442A1 IT102020000000442A IT202000000442A IT202000000442A1 IT 202000000442 A1 IT202000000442 A1 IT 202000000442A1 IT 102020000000442 A IT102020000000442 A IT 102020000000442A IT 202000000442 A IT202000000442 A IT 202000000442A IT 202000000442 A1 IT202000000442 A1 IT 202000000442A1
Authority
IT
Italy
Prior art keywords
chemotherapy
prevention
treatment
amino acids
side effects
Prior art date
Application number
IT102020000000442A
Other languages
English (en)
Inventor
Paolo Luca Maria Giorgetti
Original Assignee
Professional Dietetics Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Professional Dietetics Spa filed Critical Professional Dietetics Spa
Priority to IT102020000000442A priority Critical patent/IT202000000442A1/it
Priority to EP20216079.2A priority patent/EP3848025B9/en
Priority to CA3166643A priority patent/CA3166643A1/en
Priority to PL20216079.2T priority patent/PL3848025T3/pl
Priority to MX2022008096A priority patent/MX2022008096A/es
Priority to AU2020423611A priority patent/AU2020423611A1/en
Priority to ES20216079T priority patent/ES2954594T3/es
Priority to JP2022540340A priority patent/JP2023509627A/ja
Priority to KR1020227025981A priority patent/KR20220128629A/ko
Priority to US17/792,380 priority patent/US20230067642A1/en
Priority to PCT/IB2020/062291 priority patent/WO2021144639A1/en
Priority to BR112022013418A priority patent/BR112022013418A2/pt
Priority to CN202080093098.3A priority patent/CN114980878A/zh
Publication of IT202000000442A1 publication Critical patent/IT202000000442A1/it
Priority to CL2022001780A priority patent/CL2022001780A1/es
Priority to ZA2022/07728A priority patent/ZA202207728B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT102020000000442A 2020-01-13 2020-01-13 Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia IT202000000442A1 (it)

Priority Applications (15)

Application Number Priority Date Filing Date Title
IT102020000000442A IT202000000442A1 (it) 2020-01-13 2020-01-13 Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia
JP2022540340A JP2023509627A (ja) 2020-01-13 2020-12-21 化学療法の副作用の予防および治療における使用のためのアミノ酸を含む組成物
KR1020227025981A KR20220128629A (ko) 2020-01-13 2020-12-21 화학요법 부작용의 예방 및 치료에 사용하기 위한 아미노산을 포함하는 조성물(compositions comprising amino acids for use in the prevention and treatment of chemotherapy side effects)
PL20216079.2T PL3848025T3 (pl) 2020-01-13 2020-12-21 Kompozycje zawierające aminokwasy do zastosowania w zapobieganiu i leczeniu skutków ubocznych chemioterapii
MX2022008096A MX2022008096A (es) 2020-01-13 2020-12-21 Composiciones que comprenden aminoacidos para su uso en la prevencion y tratamiento de los efectos secundarios de la quimioterapia.
AU2020423611A AU2020423611A1 (en) 2020-01-13 2020-12-21 Compositions comprising amino acids for use in the prevention and treatment of chemotherapy side effects
ES20216079T ES2954594T3 (es) 2020-01-13 2020-12-21 Composiciones que comprenden aminoácidos para su uso en la prevención y el tratamiento de los efectos secundarios de la quimioterapia
EP20216079.2A EP3848025B9 (en) 2020-01-13 2020-12-21 Compositions comprising amino acids for use in the prevention and treatment of chemotherapy side effects
CA3166643A CA3166643A1 (en) 2020-01-13 2020-12-21 Compositions comprising amino acids for use in the prevention and treatment of chemotherapy side effects
US17/792,380 US20230067642A1 (en) 2020-01-13 2020-12-21 Compositions comprising amino acids for use in the prevention and treatment of chemotherapy side effects
PCT/IB2020/062291 WO2021144639A1 (en) 2020-01-13 2020-12-21 Compositions comprising amino acids for use in the prevention and treatment of chemotherapy side effects
BR112022013418A BR112022013418A2 (pt) 2020-01-13 2020-12-21 Composição para uso na prevenção e/ou no tratamento de cardiotoxicidade, e, preparação combinada
CN202080093098.3A CN114980878A (zh) 2020-01-13 2020-12-21 用于预防和治疗化疗副作用的包含氨基酸的组合物
CL2022001780A CL2022001780A1 (es) 2020-01-13 2022-06-29 Composiciones que comprenden aminoácidos para su uso en la prevención y tratamiento de los efectos secundarios de la quimioterapia
ZA2022/07728A ZA202207728B (en) 2020-01-13 2022-07-12 Compositions comprising amino acids for use in the prevention and treatment of chemotherapy side effects

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102020000000442A IT202000000442A1 (it) 2020-01-13 2020-01-13 Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia

Publications (1)

Publication Number Publication Date
IT202000000442A1 true IT202000000442A1 (it) 2021-07-13

Family

ID=70009337

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102020000000442A IT202000000442A1 (it) 2020-01-13 2020-01-13 Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia

Country Status (15)

Country Link
US (1) US20230067642A1 (it)
EP (1) EP3848025B9 (it)
JP (1) JP2023509627A (it)
KR (1) KR20220128629A (it)
CN (1) CN114980878A (it)
AU (1) AU2020423611A1 (it)
BR (1) BR112022013418A2 (it)
CA (1) CA3166643A1 (it)
CL (1) CL2022001780A1 (it)
ES (1) ES2954594T3 (it)
IT (1) IT202000000442A1 (it)
MX (1) MX2022008096A (it)
PL (1) PL3848025T3 (it)
WO (1) WO2021144639A1 (it)
ZA (1) ZA202207728B (it)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700087359A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
CN113425707B (zh) * 2021-07-30 2022-12-30 青岛大学附属医院 壬二酸预防蒽环类抗肿瘤药物心肌毒性的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196203B1 (en) 2003-10-07 2012-08-22 Professional Dietetics S.r.l. Use of amino-acid based compositions for the treatment of sarcopenia
WO2012147901A1 (ja) * 2011-04-28 2012-11-01 味の素株式会社 抗癌剤副作用改善用組成物
US20160038565A1 (en) * 2012-06-15 2016-02-11 Gencia Corporation Methods of Mitigating Side Effects of Radiation Exposure and Chemotherapy
WO2019021135A1 (en) 2017-07-28 2019-01-31 Professional Dietetics S.P.A. COMPOSITIONS COMPRISING AMINO ACIDS FOR USE IN THE TREATMENT OF DISEASES RELATED TO MITOCHONDRIAL DYSFUNCTION

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI551288B (zh) * 2011-02-17 2016-10-01 Ea Pharma Co Ltd Antimicrobial activity enhancer for chemotherapeutic agents
US11234949B2 (en) * 2015-05-14 2022-02-01 Professional Dietetics S.P.A. Compositions comprising amino acids for use in the treatment of mucositides in neoplasia patients undergoing radiation therapy and/or chemotherapy
WO2017089612A1 (en) * 2015-11-27 2017-06-01 Doublegood Ab Food supplement and composition for treating the metabolic syndrome

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196203B1 (en) 2003-10-07 2012-08-22 Professional Dietetics S.r.l. Use of amino-acid based compositions for the treatment of sarcopenia
WO2012147901A1 (ja) * 2011-04-28 2012-11-01 味の素株式会社 抗癌剤副作用改善用組成物
US20160038565A1 (en) * 2012-06-15 2016-02-11 Gencia Corporation Methods of Mitigating Side Effects of Radiation Exposure and Chemotherapy
WO2019021135A1 (en) 2017-07-28 2019-01-31 Professional Dietetics S.P.A. COMPOSITIONS COMPRISING AMINO ACIDS FOR USE IN THE TREATMENT OF DISEASES RELATED TO MITOCHONDRIAL DYSFUNCTION

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
ABDULLAH, C.S.ALAM, S.AISHWARYA, R.MIRIYALA, S.BHUIYAN, M.A.N.PANCHATCHARAM, M.PATTILLO, C.B.ORR, A.W.SADOSHIMA, J.HILL, J.A. ET A: "Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration", SCI. REP., vol. 9, 2019, pages 2002
ANOUK E. HIENSCH ET AL: "Doxorubicin-induced skeletal muscle atrophy: Elucidating the underlying molecular pathways", ACTA PHYSIOLOGICA, vol. 229, no. 2, 10 October 2019 (2019-10-10), GB, XP055728325, ISSN: 1748-1708, DOI: 10.1111/apha.13400 *
CHOWDHURY S. ABDULLAH ET AL: "Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration", SCIENTIFIC REPORTS, vol. 9, no. 1, 14 February 2019 (2019-02-14), XP055728288, DOI: 10.1038/s41598-018-37862-3 *
CLAYCOMB, W.C.LANSON, N.A.STALLWORTH, B.S.EGELAND, D.B.DELCARPIO, J.B.BAHINSKI, A.IZZO, N.J.: "HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte", PROC. NATL. ACAD. SCI. U. S. A., vol. 95, 1998, pages 2979 - 84, XP002198161, DOI: 10.1073/pnas.95.6.2979
DAMIANI ROBERTO MARQUES ET AL: "Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone", ARCHIVES OF TOXICOLOGY, SPRINGER, DE, vol. 90, no. 9, 25 June 2016 (2016-06-25), pages 2063 - 2076, XP036606963, ISSN: 0340-5761, [retrieved on 20160625], DOI: 10.1007/S00204-016-1759-Y *
D'ANTONA, G.RAGNI, M.CARDILE, A.TEDESCO, L.DOSSENA, M.BRUTTINI, F.CALIARO, F.CORSETTI, G.BOTTINELLI, R.CARRUBA, M.O. ET AL.: "Branched-Chain Amino Acid Supplementation Promotes Survival and Supports Cardiac and Skeletal Muscle Mitochondrial Biogenesis in Middle-Aged Mice", CELL METAB., vol. 12, 2010, pages 362 - 372, XP055294173, DOI: 10.1016/j.cmet.2010.08.016
FLAMMENT, M.GUEGUEN, N.WETTERWALD, C.SIMARD, G.MALTHIERY, Y.DUCLUZEAU, P.-H.: "Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet", AM. J. PHYSIOL. ENDOCRINOL. METAB., vol. 297, 2009, pages El 162 - 70
FRONTINI, A.BERTOLOTTI, P.TONELLO, C.VALERIO, A.NISOLI, E.CINTI, S.GIORDANO, A.: "Leptin-dependent STAT3 phosphorylation in postnatal mouse hypothalamus", BRAIN RES., vol. 1215, 2008, pages 105 - 115, XP022703212, DOI: 10.1016/j.brainres.2008.03.078
GAO, J.CHEN, T.ZHAO, D.ZHENG, J.LIU, Z.: "Ginkgolide B Exerts Cardioprotective Properties against Doxorubicin-Induced Cardiotoxicity by Regulating Reactive Oxygen Species, Akt and Calcium Signaling Pathways In Vitro and In Vivo", PLOS ONE, vol. 11, 2016, pages e0168219
LAURA A.A. GILLIAM ET AL: "The anticancer agent doxorubicin disrupts mitochondrial energy metabolism and redox balance in skeletal muscle", FREE RADICAL BIOLOGY AND MEDICINE, vol. 65, 7 September 2013 (2013-09-07), US, pages 988 - 996, XP055728564, ISSN: 0891-5849, DOI: 10.1016/j.freeradbiomed.2013.08.191 *
LIONETTI, L.MOLLICA, M.P.CRESCENZO, R.D'ANDREA, E.FERRARO, M.BIANCO, F.LIVERINI, G.IOSSA, S.: "Skeletal muscle subsarcolemmal mitochondrial dysfunction in high-fat fed rats exhibiting impaired glucose homeostasis", INT. J. OBES., vol. 31, 2007, pages 1596 - 1604
LOPEZ-LLUCH, G.HUNT, N.JONES, B.ZHU, M.JAMIESON, H.HILMER, S.CASCAJO, M. V.ALLARD, J.INGRAM, D.K.NAVAS, P. ET AL.: "Calorie restriction induces mitochondrial biogenesis and bioenergetic efficiency", PROC. NATL. ACAD. SCI., vol. 103, 2006, pages 1768 - 1773
NISOLI, E.: "Mitochondrial Biogenesis in Mammals: The Role of Endogenous Nitric Oxide", SCIENCE (80-., vol. 299, 2003, pages 896 - 899, XP002536350
PALANIVEL, R.EGUCHI, M.SHURALYOVA, I.COE, I.SWEENEY, G.: "Distinct effects of short- and long-term leptin treatment on glucose and fatty acid uptake and metabolism in HL-1 cardiomyocytes", METABOLISM, vol. 55, 2006, pages 1067 - 75, XP005540358, DOI: 10.1016/j.metabol.2006.03.020
PERVIN, S.SINGH, R.HERNANDEZ, E.WU, G.CHAUDHURI, G.: "Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway", CANCER RES., vol. 67, 2007, pages 289 - 99
SINGAL, P.K.ILISKOVIC, N.: "Doxorubicin-induced cardiomyopathy", N. ENGL. J. MED., vol. 339, 1998, pages 900 - 5, XP002672469, DOI: 10.1056/NEJM199809243391307
SPARKS, L.M.XIE, H.KOZA, R.A.MYNATT, R.HULVER, M.W.BRAY, G.A.SMITH, S.R.: "A high-fat diet coordinately downregulates genes required for mitochondrial oxidative phosphorylation in skeletal muscle", DIABETES, vol. 54, 2005, pages 1926 - 33
TEDESCO, L.CORSETTI, G.RUOCCO, C.RAGNI, M.ROSSI, F.CARRUBA, M.O.VALERIO, A.NISOLI, E.: "A specific amino acid formula prevents alcoholic liver disease in rodents", AM. J. PHYSIOL. GASTROINTEST. LIVER PHYSIOL., vol. 314, 2018, pages G566 - G582, XP009511244, DOI: 10.1152/ajpgi.00231.2017
TEDESCO, L.VALERIO, A.CERVINO, C.CARDILE, A.PAGANO, C.VETTOR, R.PASQUALI, R.CARRUBA, M.O.MARSICANO, G.LUTZ, B. ET AL.: "Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes", DIABETES, vol. 57, 2008, pages 2028 - 36
VALERIO, A.CARDILE, A.COZZI, V.BRACALE, R.TEDESCO, L.PISCONTI, A.PALOMBA, L.CANTONI, O.CLEMENTI, E.MONCADA, S. ET AL.: "TNF-alpha downregulates eNOS expression and mitochondrial biogenesis in fat and muscle of obese rodents", J. CLIN. INVEST., vol. 116, 2006, pages 2791 - 8
VETTOR, R.VALERIO, A.RAGNI, M.TREVELLIN, E.GRANZOTTO, M.OLIVIERI, M.TEDESCO, L.RUOCCO, C.FOSSATI, A.FABRIS, R. ET AL.: "Exercise training boosts eNOS-dependent mitochondrial biogenesis in mouse heart: role in adaptation of glucose metabolism", AM. J. PHYSIOL. ENDOCRINOL. METAB., vol. 306, 2014, pages E519 - 28

Also Published As

Publication number Publication date
MX2022008096A (es) 2022-07-27
CL2022001780A1 (es) 2023-02-03
AU2020423611A1 (en) 2022-07-21
CN114980878A (zh) 2022-08-30
JP2023509627A (ja) 2023-03-09
ZA202207728B (en) 2023-04-26
US20230067642A1 (en) 2023-03-02
EP3848025B1 (en) 2023-06-07
PL3848025T3 (pl) 2023-10-30
CA3166643A1 (en) 2021-07-22
WO2021144639A1 (en) 2021-07-22
EP3848025C0 (en) 2023-06-07
ES2954594T3 (es) 2023-11-23
EP3848025A1 (en) 2021-07-14
BR112022013418A2 (pt) 2022-09-20
KR20220128629A (ko) 2022-09-21
EP3848025B9 (en) 2023-08-16

Similar Documents

Publication Publication Date Title
MX2022015812A (es) Inhibidores de cisteina proteasas y sus metodos de uso.
JOP20190146A1 (ar) تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CO2017008862A2 (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n’-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quinoxalin-6-il]etano-1,2-diamina
MX2019007587A (es) Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
IT202000000442A1 (it) Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia
PH12018502634A1 (en) Topical compositions of apremilast
BRPI0407922A (pt) derivados de isoquinolina e métodos de uso destes
IT201700087359A1 (it) Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
PH12019550263A1 (en) A Pharmaceutical Composition for Anaemia
BR112018013227A2 (pt) ?composições farmacêuticas ou kit para o uso, métodos para tratar câncer em um mamífero e uso de uma composição?
ZA202007834B (en) Compositions comprising amino acids for use in the prevention and treatment of liver diseases
MX2018014631A (es) Formulacion de neurotoxina.
MA52961A (fr) Compositions et procédés pour la réduction ou le traitement d'une inflammation
IT201900021564A1 (it) Composizione nutraceutica o farmaceutica comprendente ferro pirofosfato per l’uso nel trattamento e/o nella prevenzione di condizioni o patologie caratterizzate da carenza di ferro
BR112023023463A2 (pt) Inibidores da interação menin-mll
PH12019501999A1 (en) Pyrazole derivatives as bromodomain inhibitors
EP3913002A4 (en) USE OF ECM1 IN THE PREVENTION AND/OR TREATMENT OF DISEASES RELATED TO HEPATIC FIBROSIS
MA48464A (fr) Dipeptides n-acétylés et non acétylés contenant de l'arginine destinés à réduire la viscosité de compositions visqueuses de polypeptides thérapeutiques
IT201700085412A1 (it) Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare
MX2022007175A (es) Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina.
IT202000000454A1 (it) Composizioni comprendenti amino acidi per la prevenzione e il trattamento del cancro
ATE402702T1 (de) Antiinfektiva und/oder immunmodulatoren zur präventiven therapie nach akutem schlaganfall
IT201700087376A1 (it) Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
MA49092A (fr) Compositions et procédés pour la préparation d'acides , -insaturés
IT201800002359A1 (it) “composizione ad attivita’ immunomodulatoria e relativo kit per uso nel trattamento e nella prevenzione dell’onicomicosi"